secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0000950170-24-138563
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology prioritizes PYX-201 after 50% ORR in HNSCC; suspends PYX-106
---------------------------------------------------------------------------

- Confirmed 50% ORR and 100% DCR in 6 heavily pretreated HNSCC patients in Phase 1 of PYX-201.
- Across 6 solid tumor types (n=31), PYX-201 achieved 26% ORR with dose-dependent responses in taxane-pretreated patients.
- PYX-106 program suspended; Phase 1 monotherapy enrolled 45 patients, was safe and well-tolerated.
- Current cash position expected to fund PYX-201 monotherapy and combination trials into 2H 2026.
- Monotherapy and pembrolizumab combination trials for PYX-201 expected to start dosing in early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024138563/0000950170-24-138563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024138563/pyxs-20241219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-138563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer